ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GTHR GeneThera Inc (CE)

0.000001
0.00 (0.00%)
04 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
GeneThera Inc (CE) USOTC:GTHR OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.00 01:00:00

Notification That Annual Report Will Be Submitted Late (nt 10-k)

29/03/2019 10:15am

Edgar (US Regulatory)


 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
 
 
( Check One ):
☒ Form 10-K
☐ Form 20-F
☐ Form 11-K
☐ Form 10-Q
☐ Form 10-D
☐ Form N-SAR
☐ Form N-CSR
 
For Period Ended: December 31, 2018
 
 
☐ Transition Report on Form 10-K
 
☐ Transition Report on Form 20-F
 
☐ Transition Report on Form 11-K
 
☐ Transition Report on Form 10-Q
 
☐ Transition Report on Form N-SAR
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the items(s) to which the notification relates:
 
PART I
REGISTRANT INFORMATION
 
GENETHERA, INC.
Full Name of Registrant:
 
N/A
Former Name if Applicable
 
6860 Broadway
Address of Principal Executive Office (Street and Number)
 
Denver, CO 80221
City, State and Zip Code
 
 
1
 
 
PART II
RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 

(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, 10-Q, Form N-SAR, or portion thereof, will be filed on or before the nineteenth calendar day following the prescribed due date; or the subject quarterly of transition report on Form 10-K, or portion thereof be filed on or before the fifth calendar day following prescribed due date; and
 
 
     
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
PART III
NARRATIVE
 
State below in reasonable detail the reasons why the Form 10-K, 11-K, 20-F, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
The Company is unable to file its Annual Report on Form 10-K for the period ended December 31, 2018 within the prescribed period due to the fact that on 12-6-2018, our investor, FOGT aka Fredric Oeschger, breached the contract agreement with GeneThera. This situation has created a setback preventing the Company from filing the Annual Report with unreasonable effort or expense. The Company management fully expects to be able to file within the additional time allowed by this report.
 
PART IV
OTHER INFORMATION
 
(1)
Name and telephone number of person to contact in regard to this notification.
 
 
Tannya L. Irizarry
(303)
 506-9367
 
 
(Name)
(Area Code)
(Telephone Number)
 
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  ☐ Yes ☒ No
 
 
2
 
 
GENETHERA, INC.
(Name of Registrant as Specified in Charter)
 
 
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
Date: March 28, 2019
By: /s/ TANNYA L. IRIZARRY
 
      Tannya L. Irizarry
 
         CFO (Interim)
 
 
 
 
 
 
 
 
 
 
 
3

1 Year GeneThera (CE) Chart

1 Year GeneThera (CE) Chart

1 Month GeneThera (CE) Chart

1 Month GeneThera (CE) Chart

Your Recent History

Delayed Upgrade Clock